Lyell Immunopharma (LYEL) Depreciation & Amortization (CF) (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 32.23% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $10.4 million (down 42.21% YoY), and the FY2025 full-year result was $11.5 million, down 41.22% from the prior year.
• Depreciation & Amortization (CF) declined to $2.3 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.1 million in Q3 2023 to a low of $2.3 million in Q1 2026.
• A 5-year average of $4.2 million and a median of $4.7 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) jumped 113.84% in 2022 and slumped 52.31% in 2025, its largest moves.
• Tracing LYEL's Depreciation & Amortization (CF) over 5 years: stood at $5.0 million in 2022, then advanced by 0.32% to $5.1 million in 2023, then declined by 0.61% to $5.0 million in 2024, then tumbled by 52.31% to $2.4 million in 2025, then slipped by 2.71% to $2.3 million in 2026.
• Business Quant data shows LYEL's Depreciation & Amortization (CF) at $2.3 million in Q1 2026, $2.4 million in Q4 2025, and $2.6 million in Q3 2025.